Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Bolt Biotherapeutics's Return On Capital Employed Overview

Bolt Biotherapeutics (NASDAQ:BOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 16.08%, resulting in a loss of $27.16 million. Bolt Biotherapeutics collected $752.00 thousand in revenue during Q3, but reported earnings showed a $23.39 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.